Different infusion times of tislelizumab after liver cancer surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether giving tislelizumab (an immunotherapy drug) at different infusion times after surgery can lower the chance of liver cancer coming back in people at high risk of recurrence.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have been diagnosed with hepatocellular carcinoma (liver cancer) for the first time.
- You had surgery to remove your tumor and are at high risk of the cancer coming back (e.g., tumor larger than 5 cm, positive margin, or microvascular invasion).
- You have no signs of cancer spread outside the liver before or after surgery.
- Your liver function is good (Child-Pugh class A) and you haven't received any other cancer treatment after surgery.
- You are willing to use effective contraception during the study and for 4 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether giving lenvatinib and immunotherapy along with TACE (a liver artery treatment) before surgery can lower the risk of hepatocellular carcinoma coming back after surgery. It targets people with certain higher-risk early-stage liver tumors (CNLC IB/IIA).
This trial tests whether giving a combination of chemotherapy, immunotherapy, and targeted therapy before surgery can shrink liver cancer and reduce the chance of it coming back, compared to going straight to surgery. The treatment includes medicines like pembrolizumab (sintilimab) and a drug that blocks blood vessel growth (bevacizumab).
This trial tests whether giving an immunotherapy drug (sintilimab) after surgery helps keep liver cancer with microscopic blood vessel invasion from coming back. It may improve chances of staying cancer-free after surgery.
This Phase 2 trial tests tislelizumab (an immunotherapy medicine) given after liver-directed radiation to help prevent hepatocellular carcinoma (liver cancer) from coming back or spreading. It may help by boosting the immune system to better control remaining cancer.
This trial studies whether taking tislelizumab alone or with lenvatinib before surgery can shrink recurrent liver cancer and improve outcomes. It may help by treating the cancer earlier (before the tumor is removed).
This trial tests whether a combination of two drugs (tislelizumab and lenvatinib) given before surgery can lower the risk of liver cancer coming back in people with early-stage but high-risk disease.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.